Renal Cell Carcinoma Highlights From ASCO Genitourinary Cancers Symposium 2022

Brian Shuch, MD


March 11, 2022

Dr Brian Shuch, director of the UCLA Kidney Cancer Program in Los Angeles, shares clinical and research highlights in renal cell carcinoma (RCC) presented at the 2022 ASCO Genitourinary Cancers Symposium.

He begins with 30-month follow-up data from KEYNOTE-564, on pembrolizumab as post-nephrectomy adjuvant therapy in patients at high risk for recurrence. The original clinically meaningful improvement in disease-free survival was maintained.

Dr Shuch next discusses the NeoAvAx trial, again in patients with localized, high-risk RCC. Here, neoadjuvant avelumab plus axitinib achieved an encouraging partial response in the primary tumor associated with disease-free survival.

He then reports on the Cohort A data from the HCRN GU16-260 trial of treatment-naive patients with clear cell RCC. Here, nivolumab monotherapy was active and its efficacy correlated with tumor PD-L1 status. However, salvage nivolumab plus ipilimumab offered few benefits.

Dr Shuch moves on to a study on the impact of a probiotic on nivolumab/ipilimumab combination therapy in metastatic RCC. The results indicated that it improved not only microbiome function but possibly also clinical outcomes.

Last is a large retrospective analysis indicating that the presence of pancreatic metastases in patients with RCC was associated with an improved outcome when first-line therapy included VEGF monotherapy.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.